BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 22678057)

  • 1. Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.
    Biswas K; Das R; Eggington JM; Qiao H; North SL; Stauffer S; Burkett SS; Martin BK; Southon E; Sizemore SC; Pruss D; Bowles KR; Roa BB; Hunter N; Tessarollo L; Wenstrup RJ; Byrd RA; Sharan SK
    Hum Mol Genet; 2012 Sep; 21(18):3993-4006. PubMed ID: 22678057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction with PALB2 Is Essential for Maintenance of Genomic Integrity by BRCA2.
    Hartford SA; Chittela R; Ding X; Vyas A; Martin B; Burkett S; Haines DC; Southon E; Tessarollo L; Sharan SK
    PLoS Genet; 2016 Aug; 12(8):e1006236. PubMed ID: 27490902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasticity of BRCA2 function in homologous recombination: genetic interactions of the PALB2 and DNA binding domains.
    Siaud N; Barbera MA; Egashira A; Lam I; Christ N; Schlacher K; Xia B; Jasin M
    PLoS Genet; 2011 Dec; 7(12):e1002409. PubMed ID: 22194698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.
    Park JY; Singh TR; Nassar N; Zhang F; Freund M; Hanenberg H; Meetei AR; Andreassen PR
    Oncogene; 2014 Oct; 33(40):4803-12. PubMed ID: 24141787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2.
    Zhang F; Fan Q; Ren K; Andreassen PR
    Mol Cancer Res; 2009 Jul; 7(7):1110-8. PubMed ID: 19584259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional variant analyses (FVAs) predict pathogenicity in the BRCA1 DNA double-strand break repair pathway.
    Loke J; Pearlman A; Upadhyay K; Tesfa L; Shao Y; Ostrer H
    Hum Mol Genet; 2015 Jun; 24(11):3030-7. PubMed ID: 25652403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis for recruitment of BRCA2 by PALB2.
    Oliver AW; Swift S; Lord CJ; Ashworth A; Pearl LH
    EMBO Rep; 2009 Sep; 10(9):990-6. PubMed ID: 19609323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
    Foo TK; Tischkowitz M; Simhadri S; Boshari T; Zayed N; Burke KA; Berman SH; Blecua P; Riaz N; Huo Y; Ding YC; Neuhausen SL; Weigelt B; Reis-Filho JS; Foulkes WD; Xia B
    Oncogene; 2017 Jul; 36(29):4161-4170. PubMed ID: 28319063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.
    Bowman-Colin C; Xia B; Bunting S; Klijn C; Drost R; Bouwman P; Fineman L; Chen X; Culhane AC; Cai H; Rodig SJ; Bronson RT; Jonkers J; Nussenzweig A; Kanellopoulou C; Livingston DM
    Proc Natl Acad Sci U S A; 2013 May; 110(21):8632-7. PubMed ID: 23657012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PALB2 is an integral component of the BRCA complex required for homologous recombination repair.
    Sy SM; Huen MS; Chen J
    Proc Natl Acad Sci U S A; 2009 Apr; 106(17):7155-60. PubMed ID: 19369211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PALB2 links BRCA1 and BRCA2 in the DNA-damage response.
    Zhang F; Ma J; Wu J; Ye L; Cai H; Xia B; Yu X
    Curr Biol; 2009 Mar; 19(6):524-9. PubMed ID: 19268590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the link between MORF4L1 and risk of breast cancer.
    Martrat G; Maxwell CM; Tominaga E; Porta-de-la-Riva M; Bonifaci N; Gómez-Baldó L; Bogliolo M; Lázaro C; Blanco I; Brunet J; Aguilar H; Fernández-Rodríguez J; Seal S; Renwick A; Rahman N; Kühl J; Neveling K; Schindler D; Ramírez MJ; Castellà M; Hernández G; ; Easton DF; Peock S; Cook M; Oliver CT; Frost D; Platte R; Evans DG; Lalloo F; Eeles R; Izatt L; Chu C; Davidson R; Ong KR; Cook J; Douglas F; Hodgson S; Brewer C; Morrison PJ; Porteous M; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Roversi G; Barile M; Viel A; Pasini B; Ottini L; Putignano AL; Savarese A; Bernard L; Radice P; Healey S; Spurdle A; Chen X; Beesley J; ; Rookus MA; Verhoef S; Tilanus-Linthorst MA; Vreeswijk MP; Asperen CJ; Bodmer D; Ausems MG; van Os TA; Blok MJ; Meijers-Heijboer HE; Hogervorst FB; ; Goldgar DE; Buys S; John EM; Miron A; Southey M; Daly MB; ; ; Harbst K; Borg A; Rantala J; Barbany-Bustinza G; Ehrencrona H; Stenmark-Askmalm M; Kaufman B; Laitman Y; Milgrom R; Friedman E; Domchek SM; Nathanson KL; Rebbeck TR; Johannsson OT; Couch FJ; Wang X; Fredericksen Z; Cuadras D; Moreno V; Pientka FK; Depping R; Caldés T; Osorio A; Benítez J; Bueren J; Heikkinen T; Nevanlinna H; Hamann U; Torres D; Caligo MA; Godwin AK; Imyanitov EN; Janavicius R; ; Sinilnikova OM; Stoppa-Lyonnet D; Mazoyer S; Verny-Pierre C; Castera L; de Pauw A; Bignon YJ; Uhrhammer N; Peyrat JP; Vennin P; Ferrer SF; Collonge-Rame MA; Mortemousque I; McGuffog L; Chenevix-Trench G; Pereira-Smith OM; Antoniou AC; Cerón J; Tominaga K; Surrallés J; Pujana MA
    Breast Cancer Res; 2011 Apr; 13(2):R40. PubMed ID: 21466675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene of the month: PALB2.
    Hamdan O; Nowak KM
    J Clin Pathol; 2023 Feb; 76(2):73-75. PubMed ID: 36600573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination.
    Buisson R; Dion-Côté AM; Coulombe Y; Launay H; Cai H; Stasiak AZ; Stasiak A; Xia B; Masson JY
    Nat Struct Mol Biol; 2010 Oct; 17(10):1247-54. PubMed ID: 20871615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-cancer analysis of co-occurring mutations in RAD52 and the BRCA1-BRCA2-PALB2 axis in human cancers.
    Hamid AB; Frank LE; Bouley RA; Petreaca RC
    PLoS One; 2022; 17(9):e0273736. PubMed ID: 36107942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.
    Xia B; Sheng Q; Nakanishi K; Ohashi A; Wu J; Christ N; Liu X; Jasin M; Couch FJ; Livingston DM
    Mol Cell; 2006 Jun; 22(6):719-729. PubMed ID: 16793542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRG15 binds directly to PALB2 and stimulates homology-directed repair of chromosomal breaks.
    Hayakawa T; Zhang F; Hayakawa N; Ohtani Y; Shinmyozu K; Nakayama J; Andreassen PR
    J Cell Sci; 2010 Apr; 123(Pt 7):1124-30. PubMed ID: 20332121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compensatory functions and interdependency of the DNA-binding domain of BRCA2 with the BRCA1-PALB2-BRCA2 complex.
    Al Abo M; Dejsuphong D; Hirota K; Yonetani Y; Yamazoe M; Kurumizaka H; Takeda S
    Cancer Res; 2014 Feb; 74(3):797-807. PubMed ID: 24285729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.
    Surowy HM; Sutter C; Mittnacht M; Klaes R; Schaefer D; Evers C; Burgemeister AL; Goehringer C; Dikow N; Heil J; Golatta M; Schott S; Schneeweiss A; Bugert P; Sohn C; Bartram CR; Burwinkel B
    Breast Cancer Res Treat; 2014 Jun; 145(2):451-60. PubMed ID: 24728577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.